Tirzepatide Injection is a once-weekly dual GIP/GLP-1 receptor agonist indicated for the treatment of type 2 diabetes in adults and may support clinically meaningful weight loss when used alongside diet and exercise. It combines actions on both GIP and GLP-1 pathways to improve glycaemic control and reduce appetite.

Key Benefits

• Improves blood glucose control by enhancing insulin secretion and lowering glucagon.
• Supports weight reduction through reduced appetite and delayed gastric emptying.
• Convenient once-weekly dosing in a prefilled pen for accurate administration.

Composition

Each pen delivers: Tirzepatide (strength as labelled: 2.5 mg / 5 mg / 7.5 mg / 10 mg / 12.5 mg / 15 mg).

How It Works

Tirzepatide acts on both GIP and GLP-1 receptors, improving insulin sensitivity, reducing post-prandial and fasting glucose levels, and decreasing appetite.

Usage Directions

• Administer subcutaneously once weekly as prescribed by a healthcare professional.
• Rotate injection sites; follow the prescribed titration schedule if applicable.
• Pens are for single-patient use only — do not share pens between patients.

Possible Side Effects

• Nausea, vomiting, diarrhea, constipation
• Decreased appetite
• Injection site reactions
• Rarely pancreatitis or gallbladder disorders

Precautions

• Not indicated for type 1 diabetes or treatment of diabetic ketoacidosis.
• Inform your prescriber if you have a history of pancreatitis, medullary thyroid carcinoma, or MEN2 (multiple endocrine neoplasia type 2).
• Use under medical supervision; monitor blood glucose closely when combined with insulin or sulfonylureas.

Storage Instructions

• Store refrigerated at 2°C–8°C prior to first use; follow manufacturer instructions for storage after first use.
• Do not freeze; protect from excessive heat and light.

Manufacturer

Globalstar International